OncoSil Medical Ltd News

OncoSil Medical Ltd: Corporate Governance Statement and Appendix 4G

Sep 30 17:05

OncoSil Medical Ltd: Annual Report Differences to Appendix 4E

Sep 30 17:04

OncoSil Medical Ltd: Annual Report

Sep 30 16:54

OncoSil Medical Ltd: Peter Hall elects not to join OncoSil Board

Sep 30 07:19

OncoSil Medical Ltd: 50% Recruitment in TRIPP-FFX and PANCOSIL Clinical Trials

Sep 26 07:05

OncoSil Medical Ltd: Application for quotation of securities - OSL

Sep 18 15:31

OncoSil Medical Ltd: Results of Meeting

Sep 18 10:26

OncoSil Medical Ltd: Comparative Analysis Indicates Benefits from OncoSil

Sep 18 06:54

OncoSil Medical Ltd: Strong Market Penetration with 30th OncoSil Treatment

Sep 13 07:39

OncoSil Medical Ltd: Appointment of Peter Hall as Non-Executive Director

Aug 30 13:00

OncoSil Medical Ltd: Appendix 4E Preliminary Financial Report

Aug 30 06:59

OncoSil Medical Ltd: Notice of Extraordinary General Meeting/Proxy Form

Aug 20 06:25

OncoSil Medical Ltd: Significant Growth in Commercial Treatment Sales in Q4 FY24

Aug 15 08:13

OncoSil Medical Ltd: Successful Treatment with OncoSil Device in Turkiye

Aug 15 08:05

OncoSil Medical Ltd: Ceasing to be a substantial holder SC

Aug 14 15:02

OncoSil Medical Ltd: Prospectus

Aug 7 07:27

OncoSil Medical Ltd: Application for quotation of securities - OSL

Aug 7 07:08

OncoSil Medical Ltd: Notice of Initial Substantial Holding from SOL

Jul 31 15:14

OncoSil Medical Ltd: Quarterly Activities/Appendix 4C Cash Flow Report

Jul 31 08:18

OncoSil Medical Ltd: Becoming a substantial holder from PCG

Jul 30 12:56